香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中 基 長 壽 科 學 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：767） 截至二零二二年十二月三十一日止年度 經審核全年業績公告 及 恢復買賣 中基長壽科學集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年度之綜合業績連同前一年 之比較數字。全年業績已由本公司審核委員會（「審核委員會」）審閱。 財務摘要 • 本集團收益增加46.8%至89.7百萬港元（二零二一年：61.1百萬港元）。 ...

Financial Performance - The Group recorded total revenue of HK$33,054,000 for the six months ended 30 June 2022, a significant increase from HK$16,112,000 in the same period of 2021, representing a growth of approximately 105%[43]. - The Group achieved a profit of HK$6,437,000 for the period, compared to a loss of HK$20,851,000 in the prior year, marking a turnaround in financial performance[43]. - The basic and diluted earnings per share improved to HK$0.04 cents, compared to a loss per share of HK$0.14 cents in the previous year[44]. - The Group's consolidated net assets decreased to HK$448,434,000 as of 30 June 2022, down from HK$470,718,000 at the end of 2021[44]. - The money lending and financial advisory business generated segment revenue of approximately HK$15,101,000, up from HK$8,941,000 in the previous year, with segment profit increasing to HK$12,684,000 from HK$244,000[56]. - The Group reported a net fair value loss of approximately HK$13,414,000 on listed securities investments during the review period, compared to a net fair value gain of HK$23,853,000 in the same period last year[72]. Business Development and Strategy - The management discussion highlighted a focus on expanding product offerings and enhancing user engagement metrics[16]. - The company is actively pursuing new product development initiatives aimed at improving market competitiveness[16]. - Future outlook indicates a commitment to market expansion and potential mergers and acquisitions to drive growth[16]. - The company is exploring strategic partnerships to enhance its technological capabilities[16]. - The Group is actively identifying acquisition opportunities to enhance its industry chain in longevity science[108]. - The Group plans to establish longevity medical testing centers in 18 first and second-tier cities in China over the next three years through mergers and acquisitions and strategic cooperation[147][148]. Risk Management and Governance - The company has established a risk management committee to better navigate market uncertainties[14]. - The board of directors underwent changes, with new appointments aimed at strengthening governance and oversight[14]. - The Group's operations are primarily exposed to risks including exchange rate risk, policy risk, credit risk, and liquidity risk[163]. - The slowdown of the PRC's economic growth and tightening financial regulations may adversely affect the Group's money lending and financial advisory businesses[164]. Longevity Science Business - The longevity science business contributed HK$17,953,000 in revenue and HK$6,989,000 in segment profit, which helped cushion the overall performance of the Group[43]. - The longevity science business has established two state-of-the-art testing centers in Hong Kong, offering advanced medical tests and genetic assessments[26]. - The Company aims to expand its longevity memberships and services targeting high-net-worth individuals in PRC, Hong Kong, and Southeast Asia[31]. - The Group's two patents for early cancer screening have been approved, significantly improving the effectiveness and accuracy of cancer prevention technologies[116]. - The Group is developing the "Internet + Healthcare" longevity system platform, Zhong Ji Longevity Cloud, leveraging existing customer bases and sales channels[131]. Research and Development - The Group plans to enhance its R&D capabilities by recruiting a seasoned team, including a Nobel laureate, to support its longevity science initiatives[101]. - The R&D focus will include the development of cell and gene therapy, along with providing cell testing, banking, and therapy services[158][159]. - The scientific research team has advanced the NMN product "ZJ1" to its seventh generation, introducing longevity functional beverages to improve health and longevity[131]. - The Group aims to build a world-class R&D team and facilities to accelerate innovation in longevity biological products[108]. Market Presence and Sales - The Group has formed a sales and distribution network with over 2,000 pharmacies in PRC to sell its longevity products since June 2022[31]. - The sales of longevity biological products contributed approximately HK$14,680,000 to the revenue of the longevity science segment for the six months ended June 30, 2022[99]. - The Group anticipates achieving aggregate sales of approximately RMB 109 million across over 2,000 pharmacy outlets from now until December 2024 through China GuoYao's sales and distribution contracts[158][159]. - The Group has launched an overseas flagship store on Tmall Global for the sale of ZJ1 series nutritional supplements, which includes ZJ1 NMN multi-series longevity supplements and ZJ1 VC tablets[137]. Shareholding and Capital Structure - The total number of issued ordinary shares as of June 30, 2022, remained at 3,870,102,650, unchanged from December 31, 2021[166]. - As of June 30, 2022, Mr. Yan Li held 498,855,175 shares and a 90.76% shareholding interest in Zhong Ji 1 International Medical Group, which holds convertible notes worth HK$1,840,000,000, convertible into 9,200,000,000 shares of the Company[192]. - Mr. Li Xiaoshuang held 38,680,000 share options, entitling him to subscribe for an equivalent number of shares[192]. - The Group did not pledge any assets to banks or other financial institutions as of June 30, 2022[171].

Financial Performance - Revenue for the year ended December 31, 2021, was HK$61,119,000, a decrease of 23.6% from HK$80,022,000 in 2020[6] - Profit attributable to the owners of the Company for 2021 was HK$61,119,000, compared to a loss of HK$11,487,000 in 2020[6] - The Company declared dividends of HK$6,055,000 for 2021, recovering from a loss of HK$11,487,000 in the previous year[6] - Total revenue for 2019 was HK$145,846,000, indicating a significant decline over the past two years[6] - For the year ended December 31, 2021, the Group's revenue was HK$61,119,000, a decrease from HK$80,022,000 in 2020[12] - The Group achieved a profit for the year of HK$51,909,000, compared to a loss of HK$72,458,000 in 2020, marking a significant turnaround[12] - The net profit for the year was HK$6,200,000, a recovery from a loss of HK$10,700,000 in 2020[12] - Total comprehensive income for the year was HK$15,832,000, a year-on-year increase of 33.37 times from a loss of HK$512,555,000 in 2020[12] - Adjusted EBITDA for the reporting year was approximately HK$29,010,000, slightly down from HK$29,549,000 in 2020[72] - The Money Lending business segment recorded revenue of approximately HK$27,218,000, down from HK$61,154,000 in 2020, with no interest income recorded for the year[86][87] - The financial and investment advisory business segment generated revenue of approximately HK$11,442,000, a decrease from HK$13,151,000 in 2020, due to COVID-19 related restrictions[88] Business Strategy and Outlook - The Company is focusing on expanding its market presence and enhancing product offerings in the longevity science sector[5] - Future outlook includes potential new product launches and technological advancements in longevity science[5] - The management is committed to improving operational efficiency and exploring strategic partnerships for growth[5] - The Company aims to recover from previous losses and return to profitability in the upcoming fiscal periods[5] - Ongoing research and development efforts are expected to drive innovation and market competitiveness[5] - The Group plans to implement a "supply chain finance + longevity science" dual-drive model for sustainable development[36][40] - The Group aims to develop financial services for the health product supply chain, targeting an estimated annual income of about HK$40 million from the milk powder industry chain[44] - The Group's strategic transformation includes dividing the lending finance business into corporate lending and mortgage loans in a strategic cooperation mode[42][45] - The Group is committed to risk control in its lending business while actively introducing longevity science as a new business to sustain healthy development[64] - The Group's long-term strategy includes transitioning from P2P lending to a focus on longevity science and healthcare solutions in the Greater China region[70] Financial Position - Total net assets for the Group increased to HK$470,718,000, representing a year-on-year growth of 3.48%[18] - Net current assets rose to HK$232,256,000, reflecting an increase of 48.76% over 2020[18] - The fair value of total financial assets for the year was HK$1,121,667,000[18] - As of December 31, 2021, the Group recorded net current assets of approximately HK$232,256,000, an increase from HK$156,120,000 in 2020[110] - The Group's cash and cash equivalents were approximately HK$19,437,000, down from HK$40,797,000 in 2020[110] - The gearing ratio of the Group as of December 31, 2021, was approximately 1.6%, unchanged from 2020[120] Operational Developments - The Group's transformation strategy included a shift from P2P lending to new money lending and financing consultation services in response to regulatory changes[11] - The Group had 3,291 money lending customers and realized an operating revenue of HK$38,660,000 from the money lending and loan interest segment in 2021[43][45] - The Group's impaired loans totaled HK$980,912,000, with a special debt settlement team established to manage collections under regulatory policies[48] - The Group's property investment business has not generated any revenue as the properties remain vacant due to their recent acquisition and the pandemic[105] - The Group will continue to monitor market conditions to find suitable tenants for its properties or consider disposing of them for capital appreciation[108] Research and Development - The Group's cancer early screening technology has obtained FDA certification for breast, prostate, and rectal cancer, with plans for domestic clinical testing this year and aims to achieve medical device certification within 1.5 to 3 years[53] - The Group's longevity biologics products received FDA certification and are currently sold in approximately 2,000 pharmacies in China, with plans to expand to 5,000 pharmacies in the next three years[58] - The longevity science business is divided into three segments: cancer prevention and early screening, longevity medical examination services, and R&D of longevity biological products, targeting high net worth individuals[49] - The Group's longevity medical health business includes advanced tumor cell screening and various health tests, contributing to its diversified revenue streams[70] Governance and Management - The board of directors includes independent non-executive directors with extensive experience in finance and management, enhancing corporate governance[144][146][148] - The Company has engaged an external service provider as company secretary to ensure compliance and governance standards[151] - The honorary chairman, Academician Randy Wayne Schekman, is a Nobel Prize laureate, adding significant scientific credibility to the company[150][152] - The management team includes individuals with diverse backgrounds in business, healthcare, and technology, enhancing the Company's strategic capabilities[136] - The Company emphasizes the importance of risk management and compliance through its various committees[144][147] Shareholder and Financial Policies - The Company aims to explore ways to improve financial performance and diversify operations into more profitable businesses[113] - The Company will consider its financial performance, earnings, and liquidity requirements when deciding on any future dividend payouts[171] - The Company did not recommend the payment of any dividend for the year ended December 31, 2021, consistent with 2020[125] - The Company has complied with relevant laws and regulations, including the Money Lenders Ordinance and the Hong Kong Companies Ordinance, for the year ended December 31, 2021[168] Changes in Board and Management - Mr. Yan Li has over 8 years of experience in advanced medical and biological technology management, and founded HK Zhong Ji 1 in 2014, which focuses on knee joint health resources[131] - Mr. Yan Yifan joined the Company as CEO in April 2022, previously serving as general manager of Mailyard Health Group since April 2021[132] - Mr. Li Xiaoshuang, an executive director since August 2021, has extensive experience in business operation and corporate management after retiring from a successful gymnastics career[136] - Mr. Wang Hongxin resigned as an executive director and ceased to act as CEO on December 8, 2021[185] - Mr. Li Jiuhua was appointed as an executive director and CEO on December 8, 2021, and resigned on April 8, 2022[185] - The Company has undergone several changes in its Board of Directors, with multiple resignations and appointments in 2021[178]

Financial Performance - The Group recorded total revenue of HK$16,112,000 for the six months ended 30 June 2021, a decrease of 23.5% compared to HK$20,956,000 for the same period in 2020 [26]. - The Group incurred a loss of HK$20,851,000 during the period, compared to a profit of HK$16,039,000 in the previous year, marking a significant downturn in financial performance [26]. - The basic and diluted loss per share was HK$0.54 cents, compared to earnings per share of HK$0.41 cents and HK$0.11 cents in the same period last year [27]. - The Group recorded net current assets of approximately HK$120,516,000 as of June 30, 2021, down from HK$156,120,000 at the end of 2020 [152]. - Cash and bank balances were approximately HK$20,300,000 as of June 30, 2021, compared to HK$40,797,000 at the end of 2020 [152]. Business Operations - The company is focusing on expanding its longevity science business, alongside its existing operations in money lending, securities, and property investment [13]. - The company aims to capture the growth potential of the longevity science industry through business diversification [13]. - The longevity science business generated revenue of HK$7.2 million and a net profit of HK$2.84 million, providing a cushion against overall losses [26]. - The Group's property investment business has not yet generated any revenue as all properties acquired during the review period remain vacant [81]. - The Group is in the process of renewing its money lenders license, which is crucial for continuing its lending operations [39]. Investment and Acquisitions - The Group acquired two examination centers in January 2021, enhancing its longevity medical testing capabilities with 19 categories of testing platforms [107]. - A memorandum of understanding was signed to acquire Asian Integrated Cell Laboratory Limited, a major FDA-registered international auto-immune cell bank, to advance cell therapies and pharmaceuticals [108]. - The Group acquired Banderland Development for RMB 154 million, which holds a 55% equity interest in Hangzhou Chengnan Hospital, enhancing its medical service capabilities [120]. - The Group plans to establish longevity medical testing centers in 18 first and second-tier cities in China over the next three years through mergers and acquisitions [146]. Research and Development - The Group appointed Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist to enhance its R&D capabilities [94]. - The scientific research team advanced the R&D of "ZJ1" to the seventh generation, introducing longevity functional beverages to promote health and longevity [122]. - The patents for the Group's early cancer screening inventions have been approved, enhancing its position in cancer prevention and early screening [107]. - The Group's two cancer early screening patents have been approved, significantly improving the effectiveness and accuracy of cancer screening [109]. - A strategic partnership was formed with Thermo Fisher Scientific to enhance the Group's R&D capabilities in longevity science and medical diagnostics [130]. Market Outlook - The longevity science industry is projected to flourish, with increasing public awareness of health and longevity post-COVID-19 pandemic [133]. - The longevity supplement market in China is projected to reach RMB 27 billion by 2023, growing at nearly 70% year-on-year [147]. - The management is confident in the business performance for the second half of the year, expecting the longevity science business to drive revenue growth [132]. Challenges and Risks - The money lending business did not generate any interest income during the period, a decline from HK$536,000 in the same period of 2020 [39]. - The Group has engaged legal advisors to pursue outstanding loans and interest receivables, indicating ongoing challenges in loan recovery [41]. - The segment profit for the same period was approximately HK$4,220,000, down from HK$19,102,000 in the previous year, attributed to a decrease in outstanding loans and interest receivables [43]. - The Group has not recognized any impairment provision for the six months ended June 30, 2021, compared to HK$120,000 for the same period in 2020 [43]. Corporate Governance - The Group's total number of issued ordinary shares remained at 3,870,102,650 as of June 30, 2021 [152]. - The Group did not have any capital commitments as of June 30, 2021, consistent with December 31, 2020 [193][194]. - There were no material contingent liabilities reported as of June 30, 2021, similar to the situation on December 31, 2020 [193][194]. - The Group has not implemented any foreign currency hedging policy but continuously monitors foreign exchange exposure due to fluctuations in Renminbi [190][192]. Shareholding Structure - Mr. Yan Li holds 9,200,000,000 shares in long position, representing 237.72% of the total shares as of June 30, 2021 [198]. - The beneficial ownership of Mr. Yan Li is 184,030,000 shares in long position, accounting for 4.76% of the total shares [198]. - Ms. Cao Xie Qiong holds 41,540,000 shares in long position, which is 1.07% of the total shares [198]. - As of June 30, 2021, no other directors or chief executives had interests or short positions in any shares or debentures of the company [199].

Financial Performance - Revenue for 2020 was HK$80,022,000, a decrease of 45% compared to HK$145,846,000 in 2019[14]. - The profit attributable to the owners of the company for 2020 was a loss of HK$11,487,000, compared to a loss of HK$825,678,000 in 2019[14]. - For the year ended December 31, 2020, the Group's revenue was approximately HK$80,022,000, with a loss of approximately HK$10,700,000[20]. - The loss for the year narrowed to approximately HK$10,700,000, significantly reduced from HK$825,969,000 in 2019, with basic and diluted loss per share at approximately HK0.30 cents[38]. - The money lending business generated segmental revenue of approximately HK$61,154,000, a decline from HK$121,973,000 in 2019, due to increased corporate debt defaults amid the pandemic[45]. - Interest income from the money lending business was approximately HK$48,081,000, a decrease from HK$85,292,000 in 2019, highlighting the impact of the challenging economic environment[45]. - The loan facilitation services business recorded no revenue for the year, down from HK$16,000 in 2019, indicating significant operational challenges[40]. - The Group incurred a net fair value loss of approximately HK$510,750,000 on listed securities investments, compared to a net fair value gain of HK$234,767,000 in 2019[49]. - The fair value of the Group's investment in Imperial Pacific shares was approximately HK$54,269,000, down from HK$558,971,000 in 2019, with a net fair value loss of approximately HK$504,702,000 recognized[55]. - The Group recorded net current assets of approximately HK$156,120,000, down from HK$299,308,000 in 2019, and cash and cash equivalents of approximately HK$40,797,000, down from HK$154,958,000 in 2019[84]. - The gearing ratio of the Group as of December 31, 2020, was approximately 1.6%, an increase from 0.7% in 2019[90]. Assets and Investments - Total assets as of December 31, 2020, amounted to HK$454,886,000, down from HK$967,369,000 in 2019, representing a decrease of approximately 53%[16]. - The company reported a significant reduction in equity investments designated at fair value through other comprehensive income, dropping to HK$73,345,000 from HK$603,385,000 in 2019[16]. - As of December 31, 2020, the consolidated net assets of the Group were approximately HK$454,886,000, down from HK$967,369,000 in 2019[39]. - The Group held an investment in 72,500,000 shares of Capital Environment, with a cost of approximately HK$25,793,000, and a fair value of HK$8,700,000 as of December 31, 2020[57]. - The Group's investment in Chuangxin Environment Holdings had a fair value of HK$8,700,000, representing 11.9% of total listed securities investments and 1.8% of total assets[60]. Strategic Focus and Growth Plans - The company plans to focus on expanding its market presence and developing new technologies in the longevity science sector[17]. - The management indicated potential for future growth through strategic partnerships and acquisitions in related industries[17]. - The company aims to leverage its existing assets and capabilities to explore new business opportunities in the health and wellness market[17]. - The Group aims to expand its longevity science business, targeting a market potential of RMB 304 billion for NMN products, with long-term growth prospects reaching a scale of over RMB 1 trillion[30]. - The Group plans to enhance its investment in longevity biological products, cell and gene therapy, and advanced medical technologies to capture market opportunities[30]. - The Group's vision is to help people live longer and healthier lives through innovative life management solutions across various sectors[34]. - The Group aims to establish a full value chain for NMN longevity biological products by leveraging its technology in longevity science, cell and gene therapies, and advanced medical technologies[28]. - The Group is committed to launching more products through various channels globally to expand its market share in longevity biological products[28]. - The Group plans to conduct mergers and acquisitions of advanced medical treatment and testing projects to refine its global layout in longevity science[24]. - The Group entered into an agreement to acquire two medical testing centers providing a total of 19 types of health index and disease detection tests[24]. Research and Development - The Group has invested in longevity science research and recruited an elite team, including Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist[24]. - The Group focused on the R&D and production of its flagship Nicotinamide Mononucleotide (NMN) product "ZJ1," with a production plant leased in California covering 36,000 square feet[71]. - The R&D team advanced the development of "ZJ1" to the fifth generation, aiming to maintain cellular dynamic equilibrium for health and longevity[71]. - The Group appointed Nobel Prize winners and biotechnology experts to strengthen its R&D capabilities in the longevity science sector[70]. - The management team is pushing forward R&D efforts, with the fifth-generation NMN seaweed capsules launched in 2021, aiming to establish a full industry chain for NMN products[79]. Corporate Governance and Structure - The Group's name change to Zhong Ji Longevity Science Group Limited marks a significant milestone in its business transformation journey[27]. - The company emphasizes the importance of independent directors in maintaining transparency and accountability in its operations[117][120]. - The governance structure is designed to ensure effective oversight and strategic direction, aligning with best practices in corporate governance[121]. - The company has a strong board composition with members possessing diverse backgrounds in law, finance, and corporate management, which supports strategic decision-making[121][124]. - The company appointed several independent non-executive directors, enhancing its governance structure[117][118][120]. - The leadership team is committed to leveraging their diverse expertise to drive growth and enhance shareholder value[109][111][115][116]. Market Trends and Economic Outlook - The global anti-aging market reached US$190 billion in 2019, growing by 8.3% year-on-year, with a similar trend observed in Mainland China[66]. - The International Monetary Fund (IMF) projects global economic growth of 5.5% in 2021, with China's GDP growth estimated at 8.1%, indicating a robust recovery and increased demand for health and longevity services[78]. Compliance and ESG Initiatives - The company has complied with relevant laws and regulations, including the Money Lenders Ordinance and the Hong Kong Companies Ordinance, for the year ended December 31, 2020[141]. - An ESG report will be published on the company's website by the end of May 2021, detailing its compliance with ESG policies[140]. - The company aims to enhance long-term performance through improvements in environmental, social, and governance matters[140]. - The company is committed to building an environmentally friendly working environment by promoting energy savings and recycling[140].

Financial Performance - For the six months ended June 30, 2020, the company recorded segment revenue of approximately HK$10,386,000, a decrease of 74.3% from HK$40,413,000 in the same period of 2019[55] - The segment profit for the same period was approximately HK$19,102,000, down 52.0% from HK$39,694,000 in the prior year[55] - For the six months ended June 30, 2020, the Group reported a net fair value loss of approximately HK$371,510,000 from listed securities investments, compared to a net fair value gain of HK$844,412,000 for the same period in 2019[70] - The Group recorded a profit of approximately HK$16,039,000 for the six months ended June 30, 2020, down 58.2% from HK$38,362,000 in the previous year[115] - Basic and diluted earnings per share were HK0.41 cents and HK0.11 cents respectively, compared to HK0.98 cents and HK0.26 cents for the same period in 2019[115] - For the six months ended June 30, 2020, the Group's revenue was approximately HK$20,956,000, a decrease of 71.9% compared to HK$74,551,000 for the same period in 2019[115] Loan and Interest Income - Interest income recorded by Joy Wealth for the six months ended June 30, 2020, was approximately HK$536,000, a significant decrease from HK$39,300,000 in the same period of 2019[45] - The Group recorded interest income of approximately HK$4,029,000 from trust beneficiary rights for the six months ended June 30, 2020, down from HK$9,087,000 for the same period in 2019[85] - The Group has prudently made a provision for impairment of approximately HK$120,000 for receivables due to the financial status of borrowers[60] - The company made impairment provisions for loan and interest receivables of approximately HK$120,000 for the six months ended June 30, 2020, while there were no provisions in the same period of 2019[55] Business Operations - The company ceased the business of loan facilitation services to allocate more resources to its principal businesses[44] - The Group continues to actively negotiate with borrowers to recover outstanding loans and interest receivables[59] - The Group has initiated legal proceedings against borrowers for outstanding loans and interest, with a hearing scheduled for September 14, 2020[61] Investments - The Group's investment in shares of Imperial Pacific amounted to approximately HK$76,490,000, representing about 3.8% of Imperial Pacific's issued share capital as of June 30, 2020[71] - The fair value of the shares of Imperial Pacific held by the Group was approximately HK$200,795,000 as of June 30, 2020, down from HK$558,971,000 as of December 31, 2019, representing 86.6% of the Group's total investment in listed securities[80] - The net fair value loss for the investment in shares of Imperial Pacific during the six months ended June 30, 2020, was approximately HK$358,176,000, compared to a net fair value gain of HK$841,169,000 for the same period in 2019[80] Current Assets and Liabilities - As of June 30, 2020, the Group had net current assets of approximately HK$330,893,000, an increase from HK$299,308,000 as of December 31, 2019[120] - Cash and bank balances were approximately HK$80,885,000, down from HK$154,958,000 as of December 31, 2019[120] - The gearing ratio as of June 30, 2020, was approximately 1.1%, up from 0.7% as of December 31, 2019[130] - The Group's debt-to-equity ratio was approximately 1.1%, an increase from 0.7% as of December 31, 2019[136] Future Outlook - The second half of the year is expected to remain challenging due to the ongoing impact of COVID-19 on the global economy[98] - The Group plans to continue expanding its business varieties to broaden income sources and seek potential investment opportunities[99] Shareholder Information - As of June 30, 2020, the total number of shares issued by the company was 3,870,102,650[195] - Ng Kwok Fai holds a long position of 2,129,143,068 shares, representing approximately 336.97% of the issued share capital[188] - Harmony Delight Holdings Limited is deemed to be interested in 10,912,000,000 shares, which is approximately 281.96% of the issued share capital[188] - Grand Harbour Finance Limited holds a long position of 2,129,143,068 shares, accounting for 55.02% of the issued share capital[188] - Success Seven Limited has a long position of 192,324,703 shares, representing 4.97% of the issued share capital[191] - Jiang Jianhui holds a long position of 2,321,467,771 shares, which is approximately 59.98% of the issued share capital[191] - Allied Summit Inc. has a long position of 580,659,755 shares, accounting for 15.00% of the issued share capital[191] - DeTai Finance Limited holds a long position of 580,659,755 shares, representing 15.00% of the issued share capital[191] - The company has not been notified of any other interests or short positions in the shares and underlying shares as of June 30, 2020[195] - Harmony Delight Holdings Limited holds convertible notes with a principal amount of HK$2,182,400,000, convertible into a maximum of 10,912,000,000 shares[195] Miscellaneous - The company did not declare an interim dividend for the six months ended June 30, 2020, consistent with the previous year[42] - The accumulated amount of loans provided by Joy Wealth Finance Limited since 2011 is approximately HK$2,536 million, unchanged from June 30, 2019[45] - The interest rates for loans during the six months ended June 30, 2020, ranged from 10% to 15%, compared to 9% to 15% in the previous year[45] - The Group had no capital commitments as of June 30, 2020, consistent with the previous year[165] - There were no material contingent liabilities reported as of June 30, 2020[167] - The Group has not implemented any foreign currency hedging policy but continuously monitors foreign exchange exposure due to fluctuations in the Renminbi[162] - The Group's corporate mission includes exploring ways to improve financial performance and diversifying into more profitable businesses[149] - The Group may consider debt and/or equity fundraising plans to meet financing needs arising from business development[151] - There have been no major subsequent events from June 30, 2020, to the date of the report[170] - As of June 30, 2020, none of the Directors or the chief executive had any interests or short positions in the shares of the Company[180] - As of June 30, 2020, the fair value of trust investments was approximately HK$35,095,000, a decrease from HK$59,755,000 as of December 31, 2019[88] - The fair value of trust investments was approximately HK$35,095,000 as of June 30, 2020, down from HK$59,755,000 as of December 31, 2019[88]

Financial Performance - For the year ended December 31, 2019, the Group's revenue was approximately HK$145,846,000, a decrease of 19.0% from HK$180,048,000 in 2018[15]. - The Group recorded a loss of approximately HK$825,969,000 for 2019, significantly improved from a loss of HK$2,196,597,000 in 2018[15]. - Basic and diluted losses per share were HK21.33 cents in 2019, compared to HK56.82 cents in 2018[15]. - The loan facilitation services segment recorded revenue of approximately HK$16,000, a significant decrease from HK$63,154,000 in 2018, and a profit of approximately HK$15,000 compared to a loss of HK$2,130,679,000 in 2018[23]. - The money lending business generated interest income of approximately HK$85,292,000 for the year, down from HK$88,212,000 in 2018, with an accumulated loan amount of approximately HK$2,536 million[26]. - The money lending segment reported revenue of approximately HK$121,973,000, an increase from HK$96,378,000 in 2018, but incurred a loss of approximately HK$815,636,000 due to an impairment of loan and interest receivables of approximately HK$920,774,000[28]. - The Group recognized a net fair value gain of approximately HK$234,767,000 from investments in listed securities, a recovery from a net fair value loss of HK$387,569,000 in 2018[30]. - The Group's consolidated net asset value was approximately HK$967,369,000, down from HK$1,566,771,000 in 2018[21]. - For the year ended December 31, 2019, the Group recorded interest income of approximately HK$14,844,000 from the Trust investment, down from HK$19,949,000 in 2018[40]. Assets and Liabilities - As of December 31, 2019, the consolidated net assets of the Group were approximately HK$967,369,000, down from HK$1,566,771,000 in 2018, representing a decrease of 38.3%[16]. - The total equity attributable to shareholders decreased to HK$967,369,000 in 2019 from HK$1,566,771,000 in 2018, reflecting a decline of 38.3%[12]. - The Group's plant and equipment value decreased to HK$339,000 in 2019 from HK$1,019,000 in 2018, indicating a reduction of 66.8%[12]. - The Group's financial assets at amortized cost decreased to HK$59,755,000 in 2019 from HK$157,295,000 in 2018, a decline of 62.0%[12]. - As of December 31, 2019, the Group's net current assets were approximately HK$299,308,000, a decrease from HK$1,038,703,000 in 2018, and cash and bank balances were approximately HK$154,958,000, down from HK$179,705,000[48][52]. - As of December 31, 2019, the Group had a gearing ratio of approximately 0.7%, with a net cash position as of December 31, 2018, and no borrowings[70]. - The fair value of the Trust investment decreased to approximately HK$59,755,000 as of December 31, 2019, compared to HK$157,295,000 in 2018[40][43]. Business Activities and Strategy - The Group's principal business activities include loan facilitation services, money lending, securities and other investments, and financial and investment advisory[17]. - The Group is focused on expanding its investment portfolio and enhancing its financial advisory services in the coming years[17]. - The Group aims to diversify its investment portfolio and seek stable and sustainable development opportunities to enhance shareholder value[41][47]. - The Group plans to utilize idle resources to purchase principal-guaranteed wealth management products with expected higher returns compared to savings deposits in the PRC[42][44]. - The Company is exploring ways to improve financial performance and diversify operations into more profitable businesses[67]. - The Company may consider debt and/or equity fundraising plans to meet financing needs arising from business development[67]. Corporate Governance and Compliance - The Group will continue to strengthen corporate governance and risk prevention mechanisms to achieve steady growth and development[47][51]. - The Group has complied with relevant laws and regulations, including the Money Lenders Ordinance and the Hong Kong Companies Ordinance, for the year ended December 31, 2019[114][117]. - The Company has adopted a treasury policy to control and govern possible future securities investments[69]. - The Company has maintained a register of interests and short positions as required by the Securities and Futures Ordinance[189]. Shareholder Information - The total number of issued shares of the Company remained unchanged at 3,870,102,650 shares as of December 31, 2019[49][53]. - The Company did not recommend the payment of any dividend for the year ended December 31, 2019[87]. - The substantial shareholder Hong Kong Financial Services Asset Management L.P. held 2,129,143,068 shares in long position, representing approximately 336.97% of the issued share capital of the Company[190]. - The Company has not entered into any arrangements enabling Directors to acquire benefits through shares or debentures during the year ended December 31, 2019[174]. Employee and Management Information - The Group employed 42 employees as of December 31, 2019, primarily located in Hong Kong and China[64]. - The Group provides in-house training programs to enhance employee skills and knowledge, along with performance reviews and bonuses[106]. - The Company has a share option scheme as incentives for employees, in addition to retirement benefits and medical insurance[106]. - Mr. Yeung Siu Keung joined the Group as a project manager on December 16, 2019, and was appointed as an executive director on December 17, 2019[92]. - The Directors who held office during the year include Mr. Yeung Siu Keung and Mr. Lee Man To, both of whom will offer themselves for re-election at the upcoming annual general meeting[171]. Other Relevant Information - The Group completed the acquisition of Sky State Holdings Limited on February 1, 2019, for a cash consideration of HK$25,000,000, which resulted in a segment revenue of approximately HK$8,941,000 and a segment loss of approximately HK$1,969,000 for the year[39][54]. - The Company has not purchased or redeemed any of its listed securities during the year, with 3,870,102,650 ordinary shares issued as of December 31, 2019[147]. - The aggregate revenue from the company's five largest customers accounted for approximately 73% of total revenue, with the largest customer representing 23%[197]. - The company had no management contracts other than employment contracts during the year[196].

Financial Performance - The Group recorded segment revenue of approximately HK$19,000 for the six months ended June 30, 2019, a significant decrease from HK$62,986,000 for the same period in 2018, reflecting a decline in loan facilitation services [31]. - The segment loss for the same period was approximately HK$1,488,000, compared to a segment loss of HK$1,663,553,000 in the previous year, indicating an improvement despite the revenue drop [31]. - The decrease in revenue was primarily attributed to reduced demand for loan facilitation services due to a slowdown in China's economy and tightening regulatory measures [31]. - The overall market conditions have pressured the Group's financial performance, necessitating a reevaluation of its service offerings and strategies moving forward [31]. Dividend and Shareholder Returns - The Board has resolved not to declare an interim dividend for the six months ended June 30, 2019, consistent with the previous year [29]. - The Group aims to diversify its investment portfolio and enhance shareholder value through stable and sustainable investments [82]. - The Company is actively seeking ways to enhance financial performance and diversify into more profitable industries while assessing existing investment portfolios [132]. Investments and Acquisitions - The acquisition of Katar Global Limited and its subsidiaries has been a key part of the Group's strategy since October 20, 2015, enhancing its service offerings in the P2P financing sector [31]. - The Group completed the acquisition of Sky State Holdings Limited on 1 February 2019, generating segment revenue of approximately HK$11.1 million and segment profits of approximately HK$2.8 million for the six months ended June 30, 2019 [84]. - The Group's investments in listed equity securities had a fair value of approximately HK$1,214.1 million as of 30 June 2019, significantly up from HK$369.7 million at the end of 2018 [45]. - The net fair value gain from these investments was approximately HK$844.4 million for the six months ended 30 June 2019, compared to a net fair value loss of HK$206.8 million in the same period of 2018 [45]. Market Conditions and Regulatory Environment - The tightening of market liquidity has led to a series of defaults, significantly impacting investment and financing activities in the market [31]. - The Group continues to monitor regulatory changes and market conditions to adapt its business strategies accordingly [31]. Financial Position and Assets - As of June 30, 2019, the Group recorded net current assets of approximately HK$1,125,709,000, an increase from HK$1,038,703,000 as of December 31, 2018 [104]. - The Group's cash and bank balances were approximately HK$104,488,000 as of June 30, 2019, down from HK$179,705,000 as of December 31, 2018 [104]. - The Group had no capital commitments as of June 30, 2019, consistent with the previous year [144]. - There were no material contingent liabilities reported as of June 30, 2019, similar to the status at the end of 2018 [145]. Corporate Governance and Risk Management - The Group plans to continue strengthening corporate governance and risk prevention mechanisms to achieve steady growth and development [100]. - The Group does not rule out the possibility of engaging in debt or equity fundraising plans to meet financing needs for business development [132]. - The Group has not implemented any foreign currency hedging policy but is continuously monitoring foreign exchange exposure due to fluctuations in Renminbi [143]. Share Capital and Options - The Group's total number of issued ordinary shares remained at 3,870,102,650 as of June 30, 2019 [110]. - The Company issued convertible notes amounting to HK$2,182,400,000, with a maximum of 10,912,000,000 shares to be issued upon full conversion [180]. - The Share Option Scheme allows for the issuance of up to 10% of the Company's shares, equating to 387,010,265 shares, as approved on 2 June 2017 [188]. - The maximum number of shares that can be issued upon exercise of share options in any 12-month period is limited to 1% of the total shares in issue unless shareholder approval is obtained [197].

Financial Performance - For the year ended December 31, 2018, the Group's revenue was approximately HK$180,048,000, a decrease of 34.1% from HK$273,347,000 in 2017[19] - The Group recorded a loss of approximately HK$2,196,597,000 in 2018, compared to a profit of HK$87,449,000 in 2017, resulting in basic and diluted losses per share of HK56.82 cents[19] - The total shareholders' equity as of December 31, 2018, was HK$1,566,771,000, down from HK$4,180,232,000 in 2017, reflecting a decline of 62.5%[117] - The Group experienced a net fair value loss of approximately HK$387,569,000 on listed securities for the year ended December 31, 2018, compared to a loss of HK$11,518,000 in 2017[30] - The profit attributable to the owners of the Company for 2018 was a loss of HK$2,199,094,000, compared to a profit of HK$82,274,000 in 2017[114] Segment Performance - The segment revenue from the operation of the P2P financing platform was approximately HK$63,154,000 in 2018, a decline of 61.6% from HK$164,730,000 in 2017[22] - The segment loss for the P2P financing platform was approximately HK$2,130,812,000 in 2018, compared to a segment profit of HK$151,055,000 in 2017[22] - The decrease in segment revenue and profit was primarily due to a reduction in the provision of P2P financing platform services during the year[22] - For the year ended December 31, 2018, the Group recorded segment revenue of approximately HK$63,154,000, a decrease from HK$164,730,000 in 2017, primarily due to reduced P2P financing platform services[27] Assets and Liabilities - As of December 31, 2018, the consolidated net assets of the Group were approximately HK$1,566,771,000, down from HK$4,180,232,000 in 2017[20] - As of December 31, 2018, the Group recorded net current assets of approximately HK$1,038,703,000, a decrease from HK$1,244,731,000 in 2017, and cash and bank balances of approximately HK$179,705,000[45] - The Group's current liabilities increased to HK$140,309,000 in 2018 from HK$125,176,000 in 2017[117] - The Group had cash and bank balances of approximately HK$179,705,000 as of December 31, 2018, down from HK$218,956,000 as of December 31, 2017[49] Corporate Governance - The Board is committed to high standards of corporate governance practices to enhance investor confidence and maximize shareholder returns[120] - The Company complied with the Corporate Governance Code provisions during the year, with some deviations noted[121] - The Board consists of three executive Directors, two non-executive Directors, and three independent non-executive Directors as of the report date[123] - The Company has established three board committees: Audit Committee, Remuneration Committee, and Nomination Committee, which are provided with sufficient resources to perform their duties[133] - The Company emphasizes strong corporate governance principles to ensure the Board operates independently and is well-informed on key strategic issues[131] Management and Leadership - Mr. Li Jiuhua has over 35 years of experience in the securities and finance industries, having been appointed as executive director and CEO in 2017[86][87] - Ms. Kuang Jiaying has 7 years of experience in investment and asset management, previously serving in various roles within the Group's peer-to-peer online financing platform[89] - The Group's management team includes experienced professionals with backgrounds in finance, business studies, and economics, enhancing its operational capabilities[88][90] Future Plans and Strategies - The Company aims to enhance its business operations and explore new opportunities in the financial services sector moving forward[21] - The Group plans to continue expanding its business varieties to broaden income sources and seek potential investment opportunities[44] - The Group aims to strengthen corporate governance and risk prevention mechanisms to improve overall system management and achieve steady growth[44] Shareholder Relations - The Group expresses gratitude to shareholders, customers, suppliers, and business partners for their continued support[84] - The Group did not recommend the payment of any dividend for the year ended December 31, 2018, consistent with the previous year[78] - The Group has not purchased, sold, or redeemed any of its shares during the year[83] Risk Management - The Group has not implemented any foreign currency hedging policy but continuously monitors foreign exchange exposure due to fluctuations in Renminbi[74] - The Group had no material contingent liabilities as of December 31, 2018[76] - The Group's strategic focus includes monitoring foreign exchange risks and considering hedging when significant impacts arise[80]